Generally speaking: as long as >=20% patients die in the placebo group and leronlimab reduces mortality by >=50%, we will score a good p-value with n=195.

The higher the mortality in the placebo group, the better the p-value assuming the same relative risk reduction...

20% vs 10% 0.03748
25% vs 12,5% 0.02
30% vs 15% 0.01

The p-value required to stop the trial early for efficacy is pre-specified in the statistical analysis plan, but unknown to us...